New methods for targeted treatment of brain disorders
DART.3-Revolutionizing Neuropsychiatric Treatment through Noninvasive, Programmable Cell-Type-Specific Neuropharmacology
['FUNDING_R01'] · DUKE UNIVERSITY · NIH-10862382
This study is looking at a new way to deliver medications directly to specific brain cells to see how they affect behavior and brain activity, which could help improve treatments for mental health conditions.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DUKE UNIVERSITY (nih funded) |
| Locations | 1 site (DURHAM, UNITED STATES) |
| Trial ID | NIH-10862382 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel approach to neuropharmacology that allows for the precise delivery of drugs to specific cell types in the brain. By utilizing a technology called DART, researchers aim to observe how these targeted drugs affect behavior and cellular dynamics in real-time. The project will explore noninvasive methods for drug delivery and expand the range of receptors that can be targeted, potentially leading to more effective treatments for neuropsychiatric conditions. Patients may benefit from a better understanding of how different brain circuits interact with medications.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with neuropsychiatric conditions who may benefit from targeted drug therapies.
Not a fit: Patients with conditions unrelated to neuropsychiatric disorders may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatments for patients with neuropsychiatric disorders.
How similar studies have performed: Previous research using targeted drug delivery methods has shown promise, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
DURHAM, UNITED STATES
- DUKE UNIVERSITY — DURHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TADROSS, MICHAEL R — DUKE UNIVERSITY
- Study coordinator: TADROSS, MICHAEL R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.